✨ Free AI Report
Mural Oncology plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Mural Oncology plc
Company Research

Mural Oncology plc: Business Overview, Financials & Competitive Analysis

Mural Oncology is a clinical-stage oncology business focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune...

Analyst-debate audio for Mural Oncology plc

AskCyborg analysts argue the bull and bear cases for Mural Oncology plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Failed clinical trials and strategic failure as independent biotech led to acquisition at modest valuation...

Read the full analyst-debate transcript →
Industry Clinical-stage Immuno-Oncology / Cytokine Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Mural Oncology plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Mural Oncology plc Overview

Pro stress-test →

Mural Oncology is a clinical-stage oncology business focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, Mural Oncology has developed a portfolio of novel, investigational cytokine therapies.

Strategic Profile

Pro stress-test →

The Company's lead product candidate, nemvaleukin alfa, is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2, while mitigating its hallmark toxicities. The company develops nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab, cutaneous melanoma and advanced solid tumors, as well as engineered interleukin-18 and tumor-targeted interleukin-12 programs.

Competitive Landscape

Pro stress-test →

Mural competed in the immuno-oncology space against established players developing checkpoint inhibitors and cytokine-based therapies. The engineered cytokine approach was less mature than checkpoint inhibitor strategies, limiting competitive positioning despite scientific merit.

Industry Context

Mural Oncology plc operates in Clinical-stage Immuno-Oncology / Cytokine Therapeutics.

Key facts

Founded: 2017 · Headquarters: Dublin, Ireland · Revenue: $0

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Mural Oncology plc.

  • Lead program (nemvaleukin alfa) faced trial discontinuation: ARTISTRY-7 in platinum-resistant ovarian cancer did not progress to final analysis based on interim overall survival data
  • Acquired by XOMA Royalty in December 2025 at $2.035/share base price ($36.2M valuation), indicating market loss of confidence
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Acquisition completed by XOMA Royalty subsidiary XRA 5 Corp
  • February 2025Interim analysis of ARTISTRY-7 trial in platinum-resistant ovarian cancer showed negative overall survival data, trial did not progress
  • +1 moreTrack every material event for Mural Oncology plc as it happens. Explore monitoring →
Get alerted when Mural Oncology plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Keytruda (pembrolizumab)PD-1 checkpoint inhibitor immunotherapy→Opdivo (nivolumab)PD-1 checkpoint inhibitor immunotherapy→IL-2 and IL-18 therapies in developmentEngineered cytokine immunotherapies→

Compare Mural Oncology plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Mural Oncology plc operates in Clinical-stage Immuno-Oncology / Cytokine Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-stage Immuno-Oncology / Cytokine Therapeutics research →
NEW · MCP server

Ask your AI assistant about Mural Oncology plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Mural Oncology plc and its top competitor on Cyborg Score”
“What did Mural Oncology plc do this quarter?”
“Is Mural Oncology plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Mural Oncology plc do?+
Mural Oncology is a clinical-stage oncology business focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune...
What is Mural Oncology plc's Cyborg Score?+
Mural Oncology plc has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Mural Oncology plc's main competitors?+
Named competitors include Keytruda (pembrolizumab), Opdivo (nivolumab), IL-2 and IL-18 therapies in development. The full competitive landscape is in the AskCyborg report.
How can I get the full Mural Oncology plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Mural Oncology plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Mural Oncology plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.